US nod for Meridian's Premier C diff assay
This article was originally published in Clinica
Meridian Bioscience has received 510(k) clearance from the US FDA for a new Clostridium difficile immunoassay. The Premier C difficile GDH assay detects a common antigen produced by toxigenic and non-toxigenic forms of C difficile bacteria, glutamate dehydrogenase (GDH). Toxigenic forms are associated with hospital and community acquired diarrhoea resulting from antibiotic therapy and can cause life-threatening inflammation of the colon. Premier GDH is designed to be used to screen patients with diarrhoea for both forms of C difficile, to identify patients with toxin-producing forms of C difficile. Cincinnati, Ohio-based Meridian says that GDH-positive samples should be re-tested with toxin-detecting tests. Premier C difficile GDH has been available in Europe and the rest of world since October 2010. Meridian's illumigene C difficile stool sample test gained US 510(k) clearance last year (www.clinica.co.uk, 14 July 2010).
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.